Modern opportunities for lifestyle changes and statin therapy in the prevention of cardiovascular diseases


Cite item

Full Text

Abstract

The presented review concerns the problem of lifestyle changes in primary and secondary prevention of cardiovascular diseases. The results of studies highlighting the positive effects of quitting smoking, controlling blood pressure, body weight and cholesterol on the risks of developing cardiovascular diseases and their complications are highlighted. Attention is paid to the principles of the formation of a healthy diet and increased physical activity. The principles of prescribing statins with different categories of cardiovascular risk of the patient with emphasis on the new statin - pitavastatin are indicated.

About the authors

M. G Bubnova

National Medical Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза 101990, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

References

  1. Townsend N, Wilson L, Bhatnagar P.et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016; 37 (42): 3232-45.
  2. Российский статистический ежегодник. 2016.
  3. Brown M.T, Bussell J.K. Medication adherence: WHO cares? Mayo Cl in Proc 2011; 86: 304-14.
  4. National Institute for Health and Care Excellence. NICE Publ ic Health Guidance 25. June 2010. https://www.nice.org.uk/guidance/ph25
  5. Piepoli M.F, Hoes A.W, Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2016; 37: 2315-81. doi: 10.1093/eurheartj/ehw106.
  6. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J 2015; 36: 1445-53.
  7. Katzmarzyk P.T, Lee I.M. Sedentary behaviour and life expectancy in the USA: a cause-deleted life table analysis. BMJ Open 2012; 2: e000828.
  8. Бубнова М.Г.*, Аронов Д.М. Методические рекомендации. Обеспечение физической активности граждан, имеющих ограничения в состоянии здоровья. Под ред. С.А.Бойцова. Кардиосоматика. 2016; 1: 5-50.
  9. Li Y, Hruby A, Bernstein A.M. et al. Saturated Fats Compared With Unsaturated Fats and Sources of Carbohydrates in Relation to Risk of Coronary Heart Disease. A Prospective Cohort Study. JACC 2015; 66 (14): 1538-48.
  10. Mensink R.P, Zock P.L, Kester A.D, Katan M.B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a metaanalysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-55.
  11. Chinen I, Shimabukuro M, Yamakawa K et al. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007; 148: 160-5.
  12. Artwohl M, Lindenmair A, Sexl V. et al. Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res 2008; 49: 2627-40.
  13. Hu F.B, Manson J.A, Willett W.C. Types of dietary fat and risk of coronary heart disease: a critical review. Am J Clin Nutr 2001; 20 (1): 5-19.
  14. Stentz F.B, Kitabchi A.E. Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem Biophys Res Commun 2006; 346: 721-6.
  15. Spigoni V, Fantuzzi F, Fontana A.et al. Stearic acid at physiologic concentrations induces in vitro lipotoxicity in circulating angiogenic cells. Atherosclerosis 2017; 265: 162-71.
  16. Sofi F, Abbate R, Gensini G.F, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010; 92: 1189-96.
  17. Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013; 368: 1279-90.
  18. He F.J, MacGregor G.A. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002; 16: 761-70.
  19. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004; 328: 1519.
  20. Weintraub W.S., Klein L.W, Seelaus P.A. et al. Importance of total life consumption of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 1985; 55: 669-72.
  21. Waters D, Lesperance J, Gladstone P et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996; 94: 614-21.
  22. Hasdai D, Garratt K.N, Grill D.E. et al. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997; 336: 755-61.
  23. Frey P, Waters D.D, DeMicco D.A. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trials). Am J Cardiol 2011; 107: 145-50.
  24. Бубнова М.Г., Аронов Д.М., Красницкий В.Б. Влияние курения на клинические эффекты годичной программы физической реабилитации больных трудоспособного возраста, перенесших острый инфаркт миокарда. CardioСоматика. 2017; 8 (2): 20-9.
  25. Prugger Ch, Wellmann J, Heidrich J. et al. on behalf of the EUROASPIRE Study Group. Passive smoking and smoking cessation among Patients with coronary heart disease across Europe: results from the EUROASPIRE III survey. Eur Heart J 2014; 35: 590-8. doi: 10.1093/eurheartj/eht538.
  26. Бокерия Л.А., Аронов Д.М., Барбараш О.Л. и др. Российские клинические рекомендации. Коронарное шунтирование больных ишемической болезнью сердца: реабилитация и вторичная профилактика. CardioСоматика. 2016; 7 (3-4): 5-71.
  27. Gambardella J, Sardu C, Sacra C, Santulli G. Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence. Atherosclerosis 2017; 257: 242-5. http://dx.doi.org/10.1016/j.atherosclerosis. 2016.12.010
  28. De Ruyter J.C, Olthof M.R, Seidell J.C, Katan M.B. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012; 367: 1397-406.
  29. Bell J.A, Hamer M, Sabia S. et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015; 65: 101-2.
  30. Шальнова С.А., Деев А.Д., Баланова Ю.А. и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика. 2017; 4: 4-10.
  31. Whelton P.K, Carey R.M, Aronow W.S. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults JACC, 2017. doi: 10.1016/j.jacc.2017.11.006.
  32. Lewington S, Clarke R, Qizilbash N.et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
  33. Wald D.S, Law M, Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300.
  34. Метельская В.А., Шальнова С.А., Деев А.Д. и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016; 19 (1): 15-23.
  35. Kotseva K, Wood D, De Bacquer D. et al. EUROASPIRE Investigators. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23: 636-48.
  36. Catapano A.L, Graham I, De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2016; 37: 2999-3058. doi: 10.1093/eurheartj/ ehw272.
  37. Ежов М.В., Сергиенко И.В., Аронов Д.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации IV пересмотра. Атеросклероз и дислипидемии. 2017; 3: 5-22.
  38. Robinson J.G, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46: 1855-62.
  39. Cannon C.P, Blazing M.A, Giugliano R.P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
  40. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
  41. Preis S.R, Hwang S.J, Coady S. et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009; 119: 1728-35.
  42. Chodick G, Shalev V, Gerber Y. et al. Longterm persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-79.
  43. Law M, Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C.
  44. Семенова А.Е., Сергиенко И.В. Место питавастатина в лечении и профилактике сердечно-сосудистых заболеваний. Атеросклероз и дислипидемии. 2017; 3: 33-45
  45. Catapano A.L. Pitavastatin: a different pharmacological profile. Clin Lipidol 2012; 7 (3): 3-9.
  46. Катапано А., Кухарчук В.В., Сергиенко И.В. и др. Питавастатин - современный статин для коррекции дислипидемии и риска сердечно-сосудистых осложнений. Резолюция экспертного совета. Атеросклероз и дислипидемии. 2017; 2: 104-6
  47. Pelliccia F, Rosano G, Marazzi G et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual anti platelet therapy. Circ J 2014; 78 (3): 679-84.
  48. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25: 2755-64.
  49. Teramoto T. Pitavastatin: cl inical effects from the LIVES Study. Atheroscler (Suppl.) 2011; 12: 285-8.
  50. Maruyama T, Takada M, Nishibori Y. et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951-9.
  51. Инструкция по медицинскому применению лекарственного препарата Ливазо. РУ ЛП-002855-090215.
  52. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dysli pidemia. Clin Lipidol 2009; 4 (3): 291-302.
  53. Borghi C, Cicero A.F.G. Which statin is the ideal statin for poly medicated patients? Clin Lipidol 2012; 7 (3): s11-s6.
  54. Hiro T, Kimura T, Morimoto T et al; JAPAN-ACS Investigators. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54: 293-302.
  55. Kodama K, Komatsu S, Ueda Y. et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound - the TOGETHAR trial. Circ J 2010; 74 (9): 1922-8.
  56. Maruyama T, Takada M, Nishibori Y. et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951-9.
  57. Takayama K, Taki W, Toma N. et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study - EPOCH-CAS Study. Cardiovasc Intervent Radiol 2014; 37: 1436-43. doi: 10.1007/s00270-013-0813-x.
  58. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholestero - lemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther 2011; 9 (5): 555-62.
  59. Kurihara Y, Douzono T, Kawakita K. et al. A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALOTM Tablet) - Drug use investigation. Jpn Pharmacol Ther 2007; 35: 9-40.
  60. Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv Ther 2011; 28 (9): 799-810.
  61. Гиляревский С.Р., Кузьмина И.М., Голшмид М.В. и др. Применение питавастатина у лиц пожилого и старческого возраста: оптимальное соотношение пользы и риска. Атеротромбоз. 2016; 2: 106-16.

Copyright (c) 2017 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies